Search Results

There are 9539 results for: content related to: Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors

  1. You have free access to this content
    Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus

    Hepatology

    Volume 62, Issue 3, September 2015, Pages: 932–954, AASLD/IDSA HCV Guidance Panel

    Version of Record online : 4 AUG 2015, DOI: 10.1002/hep.27950

  2. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)

    Hepatology

    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228

  3. You have free access to this content
    JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2

    Hepatology Research

    Volume 46, Issue 2, February 2016, Pages: 129–165, Yasuhiro Asahina, Namiki Izumi, Kumada Hiromitsu, Masayuki Kurosaki, Kazuhiko Koike, Fumitaka Suzuki, Hajime Takikawa, Atsushi Tanaka, Eiji Tanaka, Yasuhito Tanaka, Hirohito Tsubouchi, Norio Hayashi, Naoki Hiramatsu and Hiroshi Yotsuyanagi

    Version of Record online : 15 FEB 2016, DOI: 10.1111/hepr.12645

  4. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study

    Hepatology

    Paul Kwo, Norman Gitlin, Ronald Nahass, David Bernstein, Kyle Etzkorn, Sergio Rojter, Eugene Schiff, Mitchell Davis, Peter Ruane, Ziad Younes, Ronald Kalmeijer, Rekha Sinha, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott and James Witek

    Version of Record online : 22 MAR 2016, DOI: 10.1002/hep.28467

  5. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)

    Hepatology

    Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert W. Herring, Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas, Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, Rekha Sinha and James Witek

    Version of Record online : 19 FEB 2016, DOI: 10.1002/hep.28422

  6. You have free access to this content
    Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

    Hepatology

    Volume 60, Issue 1, July 2014, Pages: 37–45, Liesl M. Hagan, Mark S. Sulkowski and Raymond F. Schinazi

    Version of Record online : 14 MAY 2014, DOI: 10.1002/hep.27151

  7. You have full text access to this OnlineOpen article
    Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

    Hepatology

    Volume 61, Issue 4, April 2015, Pages: 1174–1182, Nikolien van de Ven, Joe Fortunak, Bryony Simmons, Nathan Ford, Graham S. Cooke, Saye Khoo and Andrew Hill

    Version of Record online : 9 FEB 2015, DOI: 10.1002/hep.27641

  8. You have free access to this content
    Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus

    Journal of Pharmacy and Pharmacology

    Volume 66, Issue 12, December 2014, Pages: 1653–1666, Bryant B. Summers, Joshua W. F. Beavers and Olga M. Klibanov

    Version of Record online : 31 AUG 2014, DOI: 10.1111/jphp.12294

  9. You have free access to this content
    Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin

    Hepatology

    Volume 61, Issue 2, February 2015, Pages: 471–480, Charlotte Hedskog, Brian Doehle, Krishna Chodavarapu, Viktoria Gontcharova, Javier Crespo Garcia, Robert De Knegt, Joost P.H Drenth, John G. McHutchison, Diana Brainard, Luisa M. Stamm, Michael D. Miller, Evguenia Svarovskaia and Hongmei Mo

    Version of Record online : 15 DEC 2014, DOI: 10.1002/hep.27361

  10. You have free access to this content
    Is genotype 3 of the hepatitis C virus the new villain?

    Hepatology

    Volume 59, Issue 6, June 2014, Pages: 2403–2412, Nicolas Goossens and Francesco Negro

    Version of Record online : 14 APR 2014, DOI: 10.1002/hep.26905

  11. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C–Infected Patients With Compensated and Decompensated Cirrhosis

    Hepatology

    Volume 62, Issue 3, September 2015, Pages: 715–725, Varun Saxena, Lisa Nyberg, Marypat Pauly, Aditi Dasgupta, Anders Nyberg, Barbara Piasecki, Bradley Winston, Jacquelyn Redd, Joanna Ready and Norah A. Terrault

    Version of Record online : 30 JUL 2015, DOI: 10.1002/hep.27922

  12. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials

    Hepatology

    Volume 61, Issue 6, June 2015, Pages: 1798–1808, Zobair M. Younossi, Maria Stepanova, Patrick Marcellin, Nezam Afdhal, Kris V. Kowdley, Stefan Zeuzem and Sharon L. Hunt

    Version of Record online : 18 MAR 2015, DOI: 10.1002/hep.27724

  13. You have free access to this content
    Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

    Hepatology

    Volume 61, Issue 5, May 2015, Pages: 1471–1478, Zobair M. Younossi, Yushan Jiang, Nathaniel J. Smith, Maria Stepanova and Rachel Beckerman

    Version of Record online : 23 MAR 2015, DOI: 10.1002/hep.27757

  14. You have full text access to this OnlineOpen article
    Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data

    Hepatology

    Volume 63, Issue 2, February 2016, Pages: 437–444, Julius M. Wilder, Lennox J. Jeffers, Natarajan Ravendhran, Mitchell L. Shiffman, John Poulos, Mark S. Sulkowski, Norman Gitlin, Kimberly Workowski, Yanni Zhu, Jenny C. Yang, Phillip S. Pang, John G. McHutchison, Andrew J. Muir, Charles Howell, Kris Kowdley, Nezam Afdhal and K. Rajender Reddy

    Version of Record online : 18 DEC 2015, DOI: 10.1002/hep.28334

  15. Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C

    Hepatology

    Volume 63, Issue 2, February 2016, Pages: 428–436, Alexis P. Chidi, Shari Rogal, Cindy L. Bryce, Michael J. Fine, Chester B. Good, Larissa Myaskovsky, Vinod K. Rustgi, Allan Tsung and Kenneth J. Smith

    Version of Record online : 21 DEC 2015, DOI: 10.1002/hep.28327

  16. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection

    Hepatology

    Volume 63, Issue 2, February 2016, Pages: 634–643, Travis B. Dick, Lance S. Lindberg, Debra D. Ramirez and Michael R. Charlton

    Version of Record online : 21 SEP 2015, DOI: 10.1002/hep.27920

  17. Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection

    Hepatology

    Volume 62, Issue 4, October 2015, Pages: 1047–1058, Aaron F. Carlin, Paula Aristizabal, Qinghua Song, Huan Wang, Matthew S. Paulson, Luisa M. Stamm, Robert T. Schooley and David L. Wyles

    Version of Record online : 22 AUG 2015, DOI: 10.1002/hep.27971

  18. You have free access to this content
    Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

    Hepatology

    Volume 59, Issue 5, May 2014, Pages: 1692–1705, Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Fabio Salvatore Macaluso, Antonella Plaia, Raffaele Bruno, Antonio Gasbarrini, Antonio Craxì, Calogero Cammà and on Behalf of the WEF Study Group

    Version of Record online : 1 APR 2014, DOI: 10.1002/hep.27010

  19. You have free access to this content
    Poster Session 2: Hepatitis C: Approved Therapeutic Agents

    Hepatology

    Volume 60, Issue S1, October 2014, Pages: 659A–709A,

    Version of Record online : 1 OCT 2014, DOI: 10.1002/hep.27516

  20. You have full text access to this OnlineOpen article
    Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

    Hepatology

    Volume 61, Issue 3, March 2015, Pages: 769–775, Eric Lawitz, Fred Poordad, Diana M. Brainard, Robert H. Hyland, Di An, Hadas Dvory-Sobol, William T. Symonds, John G. McHutchison and Fernando E. Membreno

    Version of Record online : 30 JAN 2015, DOI: 10.1002/hep.27567